How to Craft Your Pre-IPO Equity Story: Positioning and Messaging for Investors

The window for Hong Kong IPOs in 2025-2026 is not defined by valuation multiples alone, but by a fundamental shift in how institutional capital allocates to new listings. The HKEX’s proposed enhancements to the listing regime for specialist technology companies, effective from 31 March 2023 under Chapter 18C, have created a dedicated pathway for pre-revenue biotech and next-gen tech issuers, but the corresponding investor education burden has intensified. Concurrently, the SFC’s 2024-25 enforcement priorities have placed a premium on the accuracy and completeness of prospectus disclosures, particularly around “forward-looking statements” under the Securities and Futures Ordinance (Cap. 571). Against this backdrop, the pre-IPO equity story is no longer a marketing exercise—it is a regulatory and capital markets necessity. A poorly articulated narrative leads to a 30-50% discount on the final placement price, as evidenced by the 2024 performance of several GEM-to-Main Board transfers that failed to achieve their indicative price ranges. The cost of a misaligned message is not merely a failed roadshow; it is a permanent impairment of the issuer’s credibility with the sponsor and cornerstone investors.

The Structural Foundation: Aligning the Equity Story with HKEX Listing Rules

The equity story must be built on a regulatory framework that satisfies both the HKEX’s qualitative and quantitative listing requirements and the SFC’s standards for prospectus content. The starting point is not the narrative but the data that supports it.

Mapping the Business Model to Chapter 18C or Chapter 8. For issuers under Chapter 18C (specialist technology companies), the story must explicitly address the “expected market capitalization” threshold of HKD 10 billion for the “Qualified Sector” and the R&D expenditure ratio of at least 15% of total operating expenditure for the preceding three financial years (Rule 18C.03). The narrative cannot be generic; it must demonstrate how the company’s technology trajectory meets these hard metrics. For example, a company in the “Advanced Materials” sector must show a direct link between its patent portfolio and the revenue growth trajectory, not just describe the market size. The SFC’s “Guidance on the Disclosure of Financial Information in Prospectuses” (2023) explicitly warns against “boilerplate” language that does not tie financial data to business drivers.

The Sponsor’s Role in Narrative Construction. The sponsor (保薦人) is not a passive editor. Under the Code of Conduct for Persons Licensed by or Registered with the SFC (Cap. 571D), the sponsor must exercise “reasonable due diligence” to verify every material statement in the prospectus. This means the equity story must be auditable. Any claim of “market leadership” must be backed by a third-party market research report (e.g., Frost & Sullivan, IDC) with a defined scope and methodology. The 2024 HKEX enforcement action against a sponsor for failing to verify a client’s “first-mover advantage” claim—which resulted in a HKD 10 million fine—underscores the legal risk of a narrative that cannot be substantiated.

The “Use of Proceeds” as a Narrative Anchor. The most scrutinised section of any prospectus is the “Use of Proceeds” table. The story must not just state percentages but explain the mechanism of value creation. For a biotech issuer under Chapter 18A, the allocation of 60% of proceeds to “Phase II clinical trials” is insufficient. The narrative must detail the specific trial design, patient recruitment targets, and the regulatory pathway (e.g., NMPA vs. FDA) that the funding unlocks. The HKEX’s “Guidance Letter for Chapter 18A Biotech Companies” (HKEX-GL92-18) requires a clear timeline for each milestone, and the investor story must mirror this with precision.

Segmenting the Audience: From Cornerstone Investors to the General Public

A single narrative cannot serve all stakeholders. The pre-IPO equity story must be layered, with a core thesis that adapts to the specific information needs of cornerstone investors, institutional bookrunners, and retail participants.

The Cornerstone Investor Pitch: Risk-Adjusted Return. Cornerstone investors (基礎投資者) typically commit to a 6-month lock-up and receive a guaranteed allocation. Their primary concern is not the headline growth rate but the downside protection. The story must address the “floor” valuation, the strength of the sponsor’s underwriting, and the liquidity of the secondary market post-listing. For a 2025-2026 Main Board listing, the narrative should include a comparison of the implied forward P/E multiple against the HKEX’s “Sector Index” (e.g., Hang Seng Tech Index) as of the pricing date. The SFC’s “Code on Takeovers and Mergers and Share Buy-backs” (Cap. 571) is relevant here only if the issuer has a controlling shareholder, but the story must still pre-empt concerns about corporate governance—specifically, the composition of the audit committee and the independence of INEDs under Rule 3.10.

The Institutional Bookrunner: Scalability and Catalyst. Institutional investors (e.g., asset managers, hedge funds) focus on the “catalyst” for the stock price within 12-18 months of listing. The narrative must identify specific, verifiable events: a product launch, a regulatory approval, a partnership with a Fortune 500 company, or a debt refinancing. The story should also address the “float” and the free float adjustment factor under the Hang Seng Index methodology, as this determines index inclusion eligibility. A company with a free float of less than 15% will be excluded from benchmark indices, limiting institutional demand. The narrative must explicitly state the expected free float percentage post-listing.

Retail Investors: The Simplified Thesis. The retail tranche, governed by the “Prospectus (Exemptions) Notice” (Cap. 571, subsidiary legislation), requires a simplified story that focuses on the “brand” and “market position.” However, even this simplified version must avoid the SFC’s prohibited practices under the “Code on Marketing of Investment Products” (2024). The story cannot use superlatives like “best-in-class” without a clear, third-party ranking. The retail narrative should be a direct, three-sentence summary of the institutional pitch, stripped of financial jargon but retaining the core value driver (e.g., “We are the only company in Hong Kong licensed to manufacture X”).

The Mechanics of Messaging: Data, Visuals, and Risk Disclosure

The medium is as important as the message. The pre-IPO roadshow deck and the prospectus must use a consistent data architecture that allows investors to triangulate claims across multiple sources.

Data Visualisation as a Regulatory Tool. The HKEX’s “Guidance on the Use of Illustrations in Listing Documents” (HKEX-GL86-16) permits the use of charts and infographics, provided they do not mislead. The narrative should use a “waterfall chart” to show the progression from revenue to EBITDA to net profit, with clear annotations for non-recurring items. This is particularly important for issuers with negative working capital or high R&D costs. The story must reconcile the “adjusted net profit” (a non-HKFRS metric) with the statutory profit, as the SFC has flagged this as a common area of misrepresentation in its 2024 inspections.

The Risk Factor Section: A Narrative in Reverse. The equity story is incomplete without a robust “Risk Factors” section. The narrative should not bury risks but integrate them into the thesis. For example, a company dependent on a single supplier in the PRC must state the concentration risk in the story, then explain the mitigation (e.g., a dual-sourcing agreement with a supplier in Vietnam). The SFC’s “Thematic Review of Prospectus Disclosure” (2024) found that 35% of prospectuses failed to adequately quantify the impact of identified risks. The narrative must assign a probability and a financial impact where possible.

The “Path to Profitability” for Pre-Revenue Issuers. For issuers under Chapter 18A or 18C that are pre-revenue, the narrative must define “profitability” in terms of cash flow break-even, not accounting profit. The story should include a “cash runway” analysis that shows the number of months of operations funded by the IPO proceeds, assuming a conservative revenue projection. The HKEX’s “Guidance Letter on the Disclosure of Financial Information for Biotech Companies” (HKEX-GL92-18) requires a “liquidity and capital resources” section that projects the next 12 months. The narrative must match this projection and explain the assumptions behind the revenue forecast.

The Roadshow Execution: From Script to Q&A

The written narrative must be translated into a live presentation that anticipates the toughest questions from institutional investors. The preparation is not about memorising the script but about stress-testing the data.

The “Six-Minute Pitch” Structure. The standard roadshow format allows a 20-minute presentation, but the core thesis must be deliverable in six minutes. The structure should be: (1) the problem and the company’s unique solution (30 seconds), (2) the addressable market and the company’s market share (90 seconds), (3) the financial model and the key metrics (60 seconds), (4) the use of proceeds and the catalyst timeline (60 seconds), (5) the management team’s track record (30 seconds), and (6) the risk mitigation and governance (30 seconds). The remaining time is for Q&A. The narrative must be designed so that the six-minute version can be expanded with detailed data for the Q&A.

Handling the “Negative Question”. Every roadshow will include a question about a weakness: a declining gross margin, a regulatory investigation, or a competitor’s superior product. The narrative must have a pre-prepared “bridge” answer that acknowledges the issue, contextualises it (e.g., “the margin decline is due to a temporary investment in automation that will pay back in 18 months”), and pivots to a strength. The SFC’s “Code on Conduct for Persons Licensed by or Registered with the SFC” requires that answers to investor questions be “fair, clear, and not misleading.” The narrative cannot dodge the question; it must reframe it.

The “Post-Roadshow” Follow-Up. The equity story does not end when the roadshow concludes. The sponsor and the issuer must provide a “due diligence memorandum” to all participating investors, summarising the key points and addressing any outstanding questions. This document must be consistent with the prospectus and the roadshow deck. The SFC’s “Guidance on the Use of Electronic Roadshow Materials” (2024) requires that all materials be filed with the HKEX for at least 14 days after the listing. The narrative must be designed to be “evergreen”—it should not contain time-sensitive claims that will expire before the listing.

Three Actionable Takeaways for the Pre-IPO Team

1. Audit your equity story against the SFC’s 2024 prospectus disclosure checklist: Every claim of market position must be traceable to a named third-party report (e.g., Frost & Sullivan, IDC) with a defined methodology and date; any claim without such a source should be removed before the sponsor’s due diligence review.
2. Build a “risk-adjusted” valuation model for cornerstone discussions: Use a base case, a bear case, and a bull case for revenue and EBITDA, and present the implied valuation range in the roadshow deck to pre-empt the “valuation too high” objection.
3. Create a “Q&A playbook” with 25-30 anticipated questions: For each question, prepare a three-sentence answer that starts with a direct response, includes a data point, and ends with a forward-looking statement tied to the use of proceeds or the catalyst timeline.